The U.K.’s cost-effectiveness watchdog has tossed cold water on CSL Behring and uniQure’s pricey new hemophilia B gene therapy Hemgenix. In draft guidance, the National Institute for Health and Care ...

In recognition of Rare Disease Day and as part of its ongoing commitment to the global bleeding disorders community, CSL Behring announced today that it is donating 2 million international units (IUs) ...

CSL Ltd (ASX: CSL) shares were sold off in 2025. Let's find out why and see if this is a buying opportunity for ...

The Graft Versus Host Disease (GvHD) market across the seven major markets (7MM) is anticipated to witness substantial ...

Even at a hefty price tag of $2.5 million per treatment, oncoming gene therapies can be the most cost-effective (PDF) way for patients with hemophilia types A and B to deal with their condition.

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post ...

- 4- and 5-gram ZEMAIRA® vials may reduce the number of vials necessary for reconstitution, thereby providing convenience and lowering package waste KING OF PRUSSIA, Pa., Jan. 2, 2024 /PRNewswire/ -- ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Hemgenix will have a list price ...

HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus ...

Rare disease drugmaker CSL Behring will soon lay off dozens of employees at a manufacturing facility in Kankakee County. The biotech company disclosed it will eliminate 65 employees by May 21, ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. BRADLEY, Ill. — Nearly one week after ...